Modern management strategies for hypertrophic cardiomyopathy, including ICDs, surgical myectomy, anticoagulation, and heart transplant, have reduced disease-related mortality to 0.5% per year.
Modern management strategies, including ICDs, myectomy, and anticoagulation, have transformed HCM into a treatable condition with a low annual mortality rate of 0.5%.
Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited myocardial disorder, transformed over the last several years into a treatable condition with the emergence of effective management options that alter natural history at all ages. Now available are a matured risk stratification algorithm selecting patients for prophylactic implantable defibrillators that prevent arrhythmic sudden death; low-risk, high-benefit surgical myectomy to reverse progressive heart failure symptoms due to left ventricular outflow obstruction; anticoagulation prophylaxis to prevent atrial fibrillation-mediated embolic stroke; and heart transplant for refractory end-stage disease in the absence of obstruction. Those strategies have resulted in reduction of HCM-related morbidity and reduction of mortality to 0.5% per year.
Maron et al. (2022) conducted a review in Hypertrophic cardiomyopathy. Modern management strategies (ICDs, surgical myectomy, anticoagulation, heart transplant) was evaluated on HCM-related mortality. Modern management strategies for hypertrophic cardiomyopathy, including ICDs, surgical myectomy, anticoagulation, and heart transplant, have reduced disease-related mortality to 0.5% per year.